Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 12Other hematologic neoplasm 9Thoracic 8Lymphoid 6Gynecologic 5CNS 5Breast 4Tumor-Agnostic 3Sarcoma 2Plasma cell 2Head & Neck 2Genitourinary 2Dermatologic 2Myeloid 1Endocrine 1Classical hematology 1

Conditions

Neoplasm Metastasis 3

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Observation × Tumor-Agnostic × Clear all
NCT06745024 2026-05-04

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

NRG Oncology

Phase 3 Active not recruiting
280 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05717166 2025-12-31

SABR-SYNC

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 3 Recruiting
180 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03721341 2025-09-18

SABR-COMET 10

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 3 Active not recruiting
204 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡